ImmunityBio
IBRX
117 hedge funds and large institutions have $109M invested in ImmunityBio in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 44 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 24
22% more capital invested
Capital invested by funds: $89.2M → $109M (+$19.5M)
21% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $8.69M
1.63% less ownership
Funds ownership: 10.6% → 8.97% (-1.6%)
20% less funds holding
Funds holding: 146 → 117 (-29)
64% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.16M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.79M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.22M |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1.88M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$990K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$10.5M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$6.79M |
| 3 |
Cerity Partners
New York
|
-$5.07M |
| 4 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
-$3.74M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.99M |
IBRX Hedge Fund Activity: Q2 2023 in Review
117 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2023, worth a combined $109M — up 22% from $89.2M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of IBRX and 16 opened new positions — a net loss of 28 holders — while 24 trimmed existing stakes and 50 added.
The largest buyer was BlackRock, adding an estimated $7.16M. The largest seller was Armistice Capital, exiting entirely with an estimated $10.5M sold.
- 117 institutional investors held ImmunityBio (IBRX) as of Q2 2023, down from 146 in Q1 2023.
- Funds reported $109M of ImmunityBio stock for Q2 2023, up 22% quarter-over-quarter.
- 16 funds opened new ImmunityBio positions in Q2 2023 and 44 closed out, a net change of -28 holders.
- The largest ImmunityBio buyer in Q2 2023 was BlackRock, an estimated $7.16M added.
- The largest ImmunityBio seller in Q2 2023 was Armistice Capital, an estimated $10.5M sold.
Based on aggregated 13F filings for Q2 2023.